The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
Status:
Active, not recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, pilot trial to test the safety and efficacy of transplantation of
livers from Hepatitis C seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic
(HCV Ab+/NAT+) donors to HCV seronegative recipients on the liver transplant waitlist.
Treatment and prophylaxis will be administered, using a transmission-triggered approach for
the first scenario (HCV Ab+/NAT- donors, arm 1) and a prophylaxis approach for the later
scenario (HCV Ab+/NAT+ donors, arm 2).
Phase:
Phase 2
Details
Lead Sponsor:
Naudia Jonassaint
Collaborator:
University of Pittsburgh Medical Center
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir